Recommended in 2000 by EMEA's Committee of Proprietary Medicinal Products,the in vitro assessment of immunotoxic risk for drug candidates is an integral part of preclinical safety screenings. Indeed, immunosuppression, immunostimulation, hypersensitivity and autoimmunity are adverse effects that can be elicited by (bio)pharmaceuticals.
A number of assays, available from CROs and reagent companies, can be used to test the effects of drugs, whether intended or not, on the various players of cell-mediated immunity. In a technical article to be published in the April issue of Expert Opinion on Drug Discovery, Dr Maria Fuggetta critically reviews a selection of these assays and suggests how enhanced methodologies can improve the identification of immunological hazard.
Friday 13 February 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment